Clinical Trial Update: A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ARC1779 for Von Willebrand Disease Type 2B was withdrawn, with the study status changed to withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• ARC1779

Snippet

Sponsor: Archemix Corp. | Conditions: Von Willebrand Disease | Phase 2 | Status: WITHDRAWN